# Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor

> **NCT01845675** · PHASE2 · COMPLETED · sponsor: **Peking Union Medical College Hospital** · enrollment: 14 (actual)

## Conditions studied

- Advanced Well-differentiated Pancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** temozolomide or dacarbazine-based chemotherapy, endostatin

## Key facts

- **NCT ID:** NCT01845675
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2016-11-30
- **Final completion:** 2017-03-31
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01845675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01845675, "Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01845675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*